FAQ

NUDCD1 gene

Known as: NUDCD1, NUDC DOMAIN-CONTAINING PROTEIN 1, NudC domain containing 1 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2018
01220012018

Related topics

Related topics

1 relation

Broader (1)

Genes

Related mentions per year

Related mentions per year

1948-2018
19401960198020002020
NUDCD1 gene
Genes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
NudCD1 affects renal cell carcinoma through regulating LIS1/Dynein signaling pathway.
Renal cell carcinoma (RCC) is one of the most common malignant tumors in urogenital system with an incidence accounting for about… (More)
Is this relevant?
2017
2017
Protein interaction network of alternatively spliced NudCD1 isoforms
NudCD1, also known as CML66 or OVA66, is a protein initially identified as overexpressed in patients with chronic myelogenous… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.
PURPOSE The target antigens of graft-versus-leukemia that are tumor associated are incompletely characterized. EXPERIMENTAL… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
The Arg703Trp missense mutation in F13A1 is a de novo event.
Azuma, T., Otsuki, T., Kuzushima, K., Froelich, C.J., Fujita, S. & Yasukawa, M. (2004) Myeloma cells are highly sensitive to the… (More)
  • figure 1
Is this relevant?
2008
2008
RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells.
CML66 is a novel, promising tumor antigen; however, its biological roles remain unclear. In present study, we applied a short… (More)
Is this relevant?
2008
2008
Identification of an epitope derived from CML66, a novel tumor-associated antigen expressed broadly in human leukemia, recognized by human leukocyte antigen-A*2402-restricted cytotoxic T lymphocytes.
CML66 is a newly identified differentiation antigen that is expressed broadly in human leukemia and solid tumors, but its… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2005
2005
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells.
PURPOSE Donor lymphocyte infusion (DLI) reliably induces durable remission in 75% to 80% of patients with relapsed chronic… (More)
Is this relevant?
2004
2004
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L.
This report describes the difference in the epitope generation of two isoforms of self-tumor Ag CML66 and the regulation… (More)
Is this relevant?
2003
2003
[Cloning, prokaryotic expression of CML66 and preparation of its polyclonal antibody].
AIM To clone and express CML66 cDNA and to prepare rabbit anti-CML66 antibody. METHODS cDNA isolated from the testis using RT… (More)
Is this relevant?
2001
2001
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia.
This report describes a tumor-associated antigen, termed CML66, initially cloned from a chronic myelogenous leukemia (CML) cDNA… (More)
Is this relevant?